Dr. Chu is the founder and CEO of Molsentech, an expert in integrating semiconductor technology with biomedical diagnostics. She oversees the company’s technological vision, product innovation, and global strategic development. 

Dr. Chu holds a Ph.D. in Engineering from the National Taipei University of Technology and has over two decades of research experience in nanoelectronics and biosensing. Her expertise lies in silicon nanowire field-effect transistors (Bio-FET) and semiconductor-based bio-diagnostic platforms, with a focus on applying cutting-edge chip technology to rapid clinical diagnostics and precision medicine.

In 2014, Dr. Chu co-founded Molsentech with Dr. Ming-chou Lin, combining Taiwan’s semiconductor manufacturing strengths with biomedical needs to develop a biochip platform capable of delivering ultra-sensitive diagnostic results within three minutes. The platform’s proprietary Bio-FET signal amplification mechanism enables direct detection of nucleic acid and protein interactions without complex sample preparation, achieving true real-time, sample-to-result diagnostics.

During the COVID-19 pandemic, Dr. Chu led her team in developing the world’s first rapid COVID-19 detection biochip with PCR-level accuracy, which received Emergency Use Authorization (EUA) from Taiwan’s Ministry of Health and Welfare in 2021. This breakthrough technology has since expanded into cancer screening, veterinary oncology, and precision medicine, through collaborations with TSMC, Academia Sinica, and leading medical centers to accelerate commercialization and global expansion.

Under her leadership, Molsentech continues to advance innovation at the intersection of semiconductors and biomedicine, expanding across Asia, the United States, and Europe. The company is committed to becoming a global leader in real-time diagnostic biochip platforms—bringing precise, lab-grade testing into everyday healthcare.